| Literature DB >> 35223299 |
Ayuko Tokonami1, Ryuichi Ohta2, Yudai Tanaka2, Shiho Amano2, Chiaki Sano3.
Abstract
Pericarditis is a cardiac disease that commonly manifests with rheumatoid arthritis, and its complications are related to rheumatoid arthritis disease activity. The diagnosis can be complicated in patients with multiple extra-joint complications of rheumatoid arthritis. We report a case of pericarditis in an 82-year-old woman with few joint symptoms who was admitted to the hospital due to worsening edema of the lower legs and dyspnea, which progressed to cardiac tamponade. The patient presented with gradual onset of edema of both lower limbs and bilateral pleural effusion and was initially diagnosed with yellow nail syndrome. Ultimately, the patient was diagnosed with rheumatoid pericarditis due to a rapid increase in pericardial effusion. She was treated with non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine; however, the symptoms were progressive and required pericardiocentesis. After pericardiocentesis, the patient responded well to NSAIDs and colchicine, and systemic edema was relieved. This case highlights the fact that pericarditis associated with rheumatoid arthritis is not necessarily related to the severity of joint symptoms. Moreover, it can be difficult to differentiate pericarditis from multiple other diseases, such as yellow nail syndrome, in patients with rheumatoid arthritis who mainly have extra-articular symptoms.Entities:
Keywords: edema; pericardial effusion; rheumatoid arthritis; rheumatoid pericarditis; rural hospitals; yellow nail syndrome
Year: 2022 PMID: 35223299 PMCID: PMC8863119 DOI: 10.7759/cureus.21523
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1Yellow nails on the fingers of the patient
Figure 2Pericardial effusion on the initial CT (arrows)
CT: computed tomography
Initial laboratory data of the patient
HCV: hepatitis C virus; HIV: human immunodeficiency virus; HBs: hepatitis B surface antigen; HBc: hepatitis B core antigen; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2
| Marker | Level | Reference |
| White blood cells | 5.9 | 3.5–9.1 × 103/μL |
| Neutrophils | 78.4 | 44.0–72.0% |
| Lymphocytes | 16.3 | 18.0–59.0% |
| Monocytes | 7.9 | 0.0–12.0% |
| Eosinophils | 0.6 | 0.0–10.0% |
| Basophils | 0.4 | 0.0–3.0% |
| Red blood cells | 3.57 | 3.76–5.50 × 106/μL |
| Hemoglobin | 10.1 | 11.3–15.2 g/dL |
| Hematocrit | 31.7 | 33.4–44.9% |
| Mean corpuscular volume | 88.8 | 79.0–100.0 fl |
| Platelets | 17.9 | 13.0–36.9 × 104/μL |
| Prothrombin time-international normalized ratio | 1.4 | 0.90~1.15 |
| Activated partial thromboplastin time | 35 | 25–40 s |
| Fibrinogen | 235 | 200–400 mg/dL |
| Erythrocyte sedimentation rate | 82 | 2–10 mm/h |
| Total protein | 6.2 | 6.5–8.3 g/dL |
| Albumin | 2.7 | 3.8–5.3 g/dL |
| Total bilirubin | 0.3 | 0.2–1.2 mg/dL |
| Direct bilirubin | 0.1 | 0–0.4 mg/dL |
| Aspartate aminotransferase | 47 | 8–38 IU/L |
| Alanine aminotransferase | 36 | 4–43 IU/L |
| Alkaline phosphatase | 196 | 106–322 U/L |
| γ-Glutamyl transpeptidase | 76 | <48 IU/L |
| Lactate dehydrogenase | 315 | 121–245 U/L |
| Uric acid | 6.2 | 3.0–6.9 mg/dL |
| Blood urea nitrogen | 36.6 | 8–20 mg/dL |
| Creatinine | 1.12 | 0.40–1.10 mg/dL |
| Estimated glomerular filtration rate | 35.7 | >60.0 mL/min/L |
| Serum sodium | 141 | 135–150 mEq/L |
| Serum potassium | 3.8 | 3.5–5.3 mEq/L |
| Serum chloride | 106 | 98–110 mEq/L |
| Serum calcium | 8.3 | 3.5–5.3 mg/dL |
| Serum phosphorus | 3.3 | 0.2–1.2 mg/dL |
| Ferritin | 142.1 | 14.4–303.7 ng/mL |
| Creatinine kinase | 91 | 56–244 U/L |
| C-reactive protein | 7.78 | <0.30 mg/dL |
| Thyroid-stimulating hormone | 10.3 | 0.35–4.94 μIU/mL |
| Free T4 | 1.4 | 0.70–1.48 ng/dL |
| Vitamin B1 | 28 | 21.3–81.9 pg/mL |
| Folic acid | 8.2 | >4.0 ng/mL |
| Immunoglobin G | 1,004 | 870–1,700 mg/dL |
| Immunoglobin M | 87 | 35–220 mg/dL |
| Immunoglobin A | 408 | 110–410 mg/dL |
| Immunoglobin E | 171 | <173 mg/dL |
| HBs antigen | 0 | IU/mL |
| HBs antibody | 0 | mIU/mL |
| HBc antibody | 0 | S/CO |
| HCV antibody | 0 | S/CO |
| Syphilis treponema antibody | 0 | S/CO |
| SARS-CoV-2 antigen | Negative | |
| Antinuclear antibody | <40 | <40 |
| Homogeneous | (-) | |
| Speckled | (-) | |
| Nucleolar | (-) | |
| Peripheral | (-) | |
| Discrete | (-) | |
| Cytoplasm | (-) | |
| Proteinase 3-anti-neutrophil cytoplasmic antibody | <1.0 | <1.0 U/mL |
| Myeloperoxidase-anti-neutrophil cytoplasmic antibody | <1.0 | <1.0 U/mL |
| Anti-SS-A antibody | <1.0 | <1.0 U/mL |
| Anti-SS-B antibody | <1.0 | <1.0 U/mL |
| Anti-ds-DNA IgG antibody | <10 | IU/mL |
| Rheumatoid factor | 144 | <15 U/mL |
| Anti-citrullinated peptide antibody | >500 | <5 U/mL |
| Beta-D-glucan | 11 | <20 pg/mL |
| interferon-gamma release assays | (-) |
Figure 3Cardiac tamponade on the subsequent CT (arrows)
CT: computed tomography
Figure 4Pericardial drainage catheter for pericardiocentesis (arrow)
Figure 5Pericardial drainage catheter for pericardiocentesis (arrows)